Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

NodeGuardian

2026-03-28 19:18:22

Abstract generation in progress

Incyte (Nasdaq: INCY) will present late-breaking 54-week data for its JAK1 selective inhibitor povorcitinib in hidradenitis suppurativa (HS) at the 2026 AAD Annual Meeting. The data comes from the Phase 3 STOP-HS1 & STOP-HS2 studies, aiming to demonstrate the long-term safety and efficacy of povorcitinib. Additionally, Incyte will showcase multiple ePosters covering ruxolitinib cream (Opzelura®) and povorcitinib across atopic dermatitis, hidradenitis suppurativa, and vitiligo.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes